Pharmacogenomics (PGX)
What is Pharmacogenomics (PGX) ?
Utilizes whole exome test customized to meet the specific requirements of doctors. We convert the complex genomic information into clinical insights to help prescribe the right medications.
Please fill in the application to enroll using academic offer:
OncoRx Genomic testing for efficient cancer treatment & management
Offering world’s most trusted comprehensive genomic profiling test with in-depth insights on patients’ clinically relevant biomarkers and genomic alterations matching with FDA approved targeted therapies and immunotherapies.
OncoRx is a Next Generation Sequencing (NGS) based in vitro diagnostic test that uses targeted high throughput hybridization-based capture technology using DNA isolated from Formalin-Fixed Paraffin Embedded (FFPE) tumor tissue specimens and peripheral whole blood extracted circulating DNA.
It screens for Single Nucleotide Polymorphisms (SNPs), Insertion and Deletions (indels), Copy Number Alterations (CNAs) in 351 genes, select gene rearrangements, as well as genomic signatures including Homologous Recombination Repair (HRR) mutations, Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB).
Empowering physicians and patients with actionable and prescriptive insights for navigating cancer care.
As a trusted partner of choice in companion diagnostics, GenepoweRx helps to advance Personalized Healthcare in India by delivering diagnostic confidence through a broad range of genomic tests. Our standardized, fully-automated and cloud-supported solutions enable rapid turnaround time, empowering physicians to make the right treatment decisions more quickly.
Highlights
- Next Generation Sequencing using Illumina
- The proprietary Indian population specific database of variants
- Official partners of MSK’s Precision Oncology Knowledge Base
- OncoRx is registered as Class – C medical devices with CDSCO (Reg. No: Uppalu-Hy-der-TE/M/IVD/008407)
- Strict quality control measures at different stages of sample processing, data acquisition and analysis adhering to international clinical laboratory practice guidelines
- The test is validated in-house and the mean sequencing depth of the OncoRx is up-to 3000x with a total raw data output of 10 GB per sample
- High throughput NGS data analysis, curation, and interpretation of the mutations are performed by well-experienced clinical scientists/genome analysts and cancer genome experts
REPORT
In addition to FDA approved therapies, OncoRx also offers clinically actionable, personalized Pharmacogenomics (PGx) & Nutrigenomics (NGx) report.
PGx report helps in prescribing the right medication by studying the CPIC & PharmGkb approved Biomarkers. NGx profile helps in structuring a personalized nutrition regimen based on an individual’s genetic profile and metabolism.
- Simplified oncologist friendly report
- Clinically actionable prescriptive insights to oncologists
- Information on available active clinical trials
- Nutrigenomics (NGx)
- Druggable alterations and their associated FDA approved therapies
- personalized Pharmacogenomics (PGx)
- Recommended targeted therapies & possible mechanisms of resistance
OncoKB Therapeutic Levels of Evidence
Standard Care
01
FDA-recognized biomarker predictive of response to an FDA-approved drug in this indication
Investigational
02
Standard care biomarker recommended by the NCCN or other professional guidelines predictive of response to an FDA-approved drug in this indication
3A
Compelling clinical evidence supports the biomarker as being predictive of response to a drug in this indication
3B
Standard care or investigational biomarker predictive of response to a FDA-approved or investigational drug in another indication
Hypothetical
4
Compelling biological evidence supports the biomarker as being predictive of response to a drug
Standard Care Resistance
R1
Standard care biomarker predictive of resistance to an FDA-approved drug in this indication
Investigational Resistance
R2
Compelling clinical evidence supports the biomarker as being predictive of resistance to a drug
Biomarkers & FDA-Approved Therapy
Non-Small Cell Lung Cancer
EGFR exon 19 deletions & EGFR exon 21 , L858R alterations
Gilotrif® (afatinib), Iressa® (gefitinib), Tagrisso® (osimertinib), or Tarceva®
EGFR exon 20 T790M alterations
Tagrisso® (osimertinib)
ALK rearrangements
Alecensa® (alectinib), Alunbrig® (brigatinib) Xalkori® (crizotinib), or Zykadia® (ceritinib)
BRAF V600E
Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib)
MET single nucleotide variants (SNVs) and indels that lead to MET exon 14 skipping
TabrectaTM (capmatinib)
Breast Cancer
ERBB2 (HER2) amplification
Herceptin® (trastuzumab), Kadcyla® (ado trastuzumab-emtansine), or Perjeta® (pertuzumab)
PIK3CA C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y alterations
Piqray® (alpelisib)
Colorectal Cancer
KRAS wild-type (absence of mutations in codons 12 and 13)
Erbitux® (cetuximab)
KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4)
Vectibix® (panitumumab)
Ovarian Cancer
BRCA1/2 alterations
Lynparza® (olaparib) or Rubraca® (rucaparib)
Prostate Cancer
Homologous Recombination Repair (HRR) gene (BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L) alterations
Lynparza® (olaparib)
All Solid Tumors
TMB ≥ 10 mutations per megabase
Keytruda® (pembrolizumab)
NTRK1/2/3 fusions
Vitrakvi® (larotrectinib)
Genes screened in OncoRx Comprehensive for the detection of SNV, insertions and deletions (indels) and copy number alterations (CNAs).
- ABL1
- AKT1
- AKT2
- AKT3
- ALK
- ALOX12B
- AMER1
- APC
- AR
- ARAF
- ARFRP1
- ARID1A
- ASXL1
- ATM
- ATR
- ATRX
- AURKA
- AURKB
- AXIN1
- AXL
- BAP1
- BARD1
- BCL2
- BCL2L1
- BCL2L2
- BCL6
- BCOR
- BCORL1
- BRAF
- BRCA1
- BRCA2
- BRD4
- BRIP1
- BTG1
- BTG2
- BTK
- C11orf30
- CALR
- CARD11
- CASP8
- CBFB
- CBL
- CCND1
- CCND2
- CCND3
- CCNE1
- CD22
- CD274
- CD70
- CD79A
- CD79B
- CDC73
- CDH1
- CDK12
- CDK4
- CDK6
- CDK8
- CDKN1A
- CDKN1B
- CDKN2A
- CDKN2B
- CDKN2C
- CEBPA
- CHEK1
- CHEK2
- CIC
- CREBBP
- CRKL
- CSF1R
- CSF3R
- CTCF
- CTNNA1
- CTNNB1
- CUL3
- CUL4A
- CVR1B
- CXCR4
- CYP17A1
- DAXX
- DDR1
- DDR2
- DIS3
- DNMT3A
- DOT1L
- EED
- EGFR
- EP300
- EPHA3
- EPHB1
- EPHB4
- ERBB2
- ERBB3
- ERBB4
- ERCC4
- ERG
- ERRFI1
- ESR1
- EZH2
- FAM46C
- FANCA
- FANCC
- FANCG
- FANCL
- FAS
- FBXW7
- FGF10
- FGF12
- FGF14
- FGF19
- FGF23
- FGF3
- FGF4 ID3
- FGF6
- FGFR1
- FGFR2
- FGFR3
- FGFR4
- FH
- FLCN
- FLT1
- FLT3
- FOXL2
- FUBP1
- GABRA6
- GATA3
- GATA4
- GATA6
- GID4
- GNA11
- GNA13
- GNAQ
- GNAS
- GRM3
- GSK3B
- H3F3A
- HDAC1
- HGF
- HNF1A
- HRAS
- HSD3B1
- IDH1
- IDH2
- IGF1R
- IKBKE
- IKZF1
- INPP4B
- IRF2
- IRF4
- IRS2
- JAK1
- JAK2
- JAK3
- JUN
- KDM5A
- KDM5C
- KDM6A
- KDR
- KEAP1
- KEL
- KIT
- KLHL6
- KMT2A
- KMT2D
- KRAS
- LTK
- LYN
- MAF
- MAP2K1
- MAP2K2
- MAP2K4
- MAP3K1
- MAP3K13
- MAPK1
- MCL1
- MDM2
- MDM4
- MED12
- MEF2B
- MEN1
- MERTK
- MET
- MITF
- MKNK1
- MLH1
- MPL
- MRE11A
- MSH2
- MSH3
- MSH6
- MST1R
- MTAP
- MTOR
- MUTYH
- MYC
- MYCL
- MYCN
- MYD88
- NBN
- NF1
- NF2
- NFE2L2
- NFKBIA
- NKX2-1
- NOTCH1
- NOTCH2
- NOTCH3
- NPM1
- NRAS
- NT5C2
- NTRK1
- NTRK2
- NTRK3
- P2RY8
- PALB2
- PARK2
- PARP1
- PARP2
- PARP3
- PAX5
- PBRM1
- PDCD1
- PDCD1LG2
- PDGFRA
- PDGFRB
- PDK1
- PIK3C2B
- PIK3C2G
- PIK3CA
- PIK3CB
- PIK3R1
- PIM1
- PMS2
- POLD1
- POLE R
- PPARG
- PPP2R1A
- PPP2R2A
- PRDM1
- PRKAR1A
- PRKCI
- PTCH1
- PTEN
- PTOR
- PTPN11
- PTPRO
- QKI
- RAC1
- RAD21
- RAD51
- RAD51B
- RAD51C
- RAD51D
- RAD52
- RAD54L
- RAF1
- RARA
- RB1
- RBM10
- REL
- RET
- RICTOR
- RNF43
- ROS1
- SDHA
- SDHB
- SDHC
- SDHD
- SETD2
- SF3B1
- SGK1
- SMAD2
- SMAD4
- SMAR
- CA4
- SMARCB1
- SMO
- SNCAIP
- SOCS1
- SOX2
- SOX9
- SPEN
- SPOP
- SRC
- STAG2
- STAT3
- STK11
- SUFU
- SYK
- TBX3
- TEK
- TET2
- TGFBR2
- TIPARP
- TNFAIP3
- TNFRSF14
- TP53
- TSC1
- TSC2
- TYRO3
- U2AF1
- VEGFA
- VHL
- WHSC1
- WHSC1L1
- WT1
- XPO1
- XRCC2
- ZNF217
- ZNF703
Genomic regions screened for detection of gene rearrangements.
- ALK introns 18, 19
- BRCA1 introns 2, 7, 8, 12, 16, 19, 20
- ETV4 intron 8
- EZR introns 9- 11
- KIT intron 16
- MYC intron 1
- RET introns 7-11
- SLC34A2 intron 4
- BCL2 3’UTR
- BRCA2 intron 2
- ETV5 introns 6,
- 7FGFR1 intron 1, 5, 17
- KMT2A (MLL) introns
- NOTCH2 intron 26
- TERC ncRNA
- PDGFRA introns 7, 9, 11
- ROS1 introns 31-35
- BCR introns 8, 13, 14
- MSH2 intron
- ETV6* introns 5, 6
- FGFR2 intron 1, 17
- NTRK1 introns
- 11RAF1 introns 4-8
- RSPO2 intron 1
- TERT Promoter
- BRAF introns 7-10
- EWSR7-introns 7-13
- FGFR3 intron 17
- MYB intron 14
- NTRK2 Intron 12
- RARA intron 2
- SDC4 intron 2
- TMPRSS2 introns 1- 3
List of Genes Screened in OncoRX Mini -
Level 1 MARKERS
- ABL1
- ABL2
- ALK
- APLNR
- ATM
- B2M
- BARD1
- BRAF
- BRCA1
- BRCA2
- BRIP1
- CD274
- CD74
- CDK12
- CDKN2A
- CDKN2B
- CHEK1
- CHEK2
- EGFR
- EML4
- ERBB2
- ERG
- ETV1
- ETV4
- ETV5
- ETV6
- EZH2
- FANCA
- FANCC
- FANCD2
- FANCE
- FANCF
- FANCG
- FANCL
- FANCM
- FGFR2
- FGFR3
- FOXA1
- HLA-A
- HLA-B
- HLA-C
- IDH1
- IDH2
- KIT
- KRAS
- MET
- NAB2
- NF1
- NRAS
- NRG1
- NTRK1
- NTRK2
- NTRK3
- PALB2
- PDGFB
- PDGFRA
- PIK3CA
- PTEN
- RAD51B
- RAD51C
- RAD51D
- RAD54L
- RAF1
- RB1
- RET
- ROS1
- SLC34A2
- SMARCB1
- TERT
- TP53
- TSC1
Level 2 MARKERS
- ALK
- BRAF
- EGFR
- ERBB2
- KIT
- MET
- PDGFRA
- PIK3CA
- RET
R1 MARKERS:
- EGFR
- KRAS
- NRAS
- NTRK1
- NTRK3
- PDGFRA
OncoRx is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies in accordance with the approved therapeutic product labeling.
Treating oncologists can also decide ideal candidates who can benefit from this test by means of immunotherapies, targeted therapies and personalized pharmacogenomic.
Related Products
GenepoweRx Total
What is GenepoweRx Total ?
GenepoweRx Total is your DNA/genetic testing that can identify your risk for developing a certain disease condition or passing on a genetic disorder. The medical test offers precise treatment plan and a personalized well-being plan.
